Literature DB >> 10473721

Thyroid cancer in Wales 1985-1996: a cancer registry-based study.

I C Paterson1, R Greenlee, D Adams Jones.   

Abstract

No dedicated clinicopathological database for thyroid cancer exists in Wales to provide information about the incidence, histology, treatment and outcome of this uncommon malignancy. We have used cancer registry data to examine the epidemiology of thyroid cancer in Wales between 1985 and 1996 and have searched the database for clinically relevant data about stage, treatment and survival. A total of 699 cases were identified in this 12-year period, with no significant differences in their distribution between the five health authorities. Further analysis revealed a very wide age range (8-93 years) with a predominance of females (F:M ratio 2.8:1) and survival strongly influenced by gender, age and histological type. There were insufficient data to stage these cancers and only limited data about the surgical procedures undertaken. There was no information on non-surgical treatments (radio-iodine, radiotherapy and chemotherapy) in the database. Cancer registry data is well able to sustain an analysis of the epidemiology of thyroid cancer but further work is necessary to improve the quality of clinically relevant information about stage and treatment that could be used for audit.

Entities:  

Mesh:

Year:  1999        PMID: 10473721     DOI: 10.1053/clon.1999.9057

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  7 in total

1.  BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion.

Authors:  Avik Chakraborty; Archana Narkar; Rita Mukhopadhyaya; Shubhada Kane; Anil D'Cruz; M G R Rajan
Journal:  Endocr Pathol       Date:  2012-06       Impact factor: 3.943

2.  Pigment epithelium-derived factor has a role in the progression of papillary thyroid carcinoma by affecting the HIF1α-VEGF signaling pathway.

Authors:  Yichen Lv; Yu Sun; Tiefeng Shi; Chenlei Shi; Huadong Qin; Zhaozhu Li
Journal:  Oncol Lett       Date:  2016-10-25       Impact factor: 2.967

3.  Enhanced identification and functional protective role of carbon nanoparticles on parathyroid in thyroid cancer surgery: A retrospective Chinese population study.

Authors:  Chenlei Shi; Bo Tian; Shengze Li; Tiefeng Shi; Huadong Qin; Shaoyan Liu
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

4.  Preliminary Study on the Clinical Significance and Methods of Using Carbon Nanoparticles in Endoscopic Papillary Thyroid Cancer Surgery.

Authors:  Shangrui Rao; Zhonglin Wang; Congtao Pan; Yi Wang; Zhe Lin; Zhongliang Pan; Jian Yu
Journal:  Contrast Media Mol Imaging       Date:  2021-04-26       Impact factor: 3.161

Review 5.  Contemporary Management of Recurrent Nodal Disease in Differentiated Thyroid Carcinoma.

Authors:  Shorook Na'ara; Moran Amit; Eran Fridman; Ziv Gil
Journal:  Rambam Maimonides Med J       Date:  2016-01-28

6.  Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.

Authors:  Chenlei Shi; Yong Guo; Yichen Lv; Abiyasi Nanding; Tiefeng Shi; Huadong Qin; Jianjun He
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

7.  Evaluation of the Role of BRAFV600E Somatic Mutation on Papillary Thyroid Cancer Disease Persistence: A Prospective Study.

Authors:  Luca Damiani; Sabrina Lupo; Roberta Rossi; Stefania Bruni; Mirco Bartolomei; Stefano Panareo; Paola Franceschetti; Paolo Carcoforo; Giovanni Lanza; Stefano Pelucchi; Ettore Degli Uberti; Maria Chiara Zatelli
Journal:  Eur Thyroid J       Date:  2018-07-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.